title: The association between race and treatment regret among men with recurrent prostate cancer.
abstract: BACKGROUND
  To examine the impact of race on treatment regret among men with recurrent prostate cancer after surgery or radiation.
  
  
  METHODS
  The prospective Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma (COMPARE) registry was used to study a cohort of 484 men with biochemically recurrent prostate cancer after radical prostatectomy, external beam radiation or brachytherapy. Multivariable logistic regression was used to model the association between race and treatment regret and to determine whether there was an interaction between race and sexual problems after treatment with regards to treatment regret.
  
  
  RESULTS
  Black men (N=78) were significantly more likely to have treatment regret when compared with non-black men (N=406; 21.8% versus 12.6%) on univariable analysis (odds ratio (OR) 1.94; 95% confidence interval 1.05-3.56; P=0.03). On multivariable analysis, black race trended towards but was no longer significantly associated with an increase in treatment regret (adjusted OR (AOR) 1.84 (0.95-3.58); P=0.071). There was an interaction between race and sexual problems after treatment (Pinteraction=0.02) such that among those without sexual problems, black men had more treatment regret than non-black men (26.7% versus 8.4%: AOR 4.68 (1.73-12.63); P=0.002), whereas among those with sexual problems, there was no difference in treatment regret between black and non-black men (18.8% versus 17.3%: AOR 1.04 (0.44-2.46); P=0.93).
  
  
  CONCLUSIONS
  Among men with recurrent prostate cancer after surgery or radiation, black men were nearly twice as likely to experience treatment regret. Treating physicians should ensure that patients are fully apprised of the pros and cons of all treatment options to reduce the risk of subsequent regret.
authors.affiliation: Harvard Medical School, Boston, MA, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Mahal
authors.affiliation: Department of Statistics, University of Connecticut, Storrs, CT, USA.
authors.forename: M-H
authors.initials: MH
authors.lastname: Chen
authors.affiliation: South Carolina College of Pharmacy, Hollings Cancer Center, Charleston, SC, USA.
authors.forename: C L
authors.initials: CL
authors.lastname: Bennett
authors.affiliation: Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: M W
authors.initials: MW
authors.lastname: Kattan
authors.affiliation: Department of Medicine and Urology, Tulane University, New Orleans, LA, USA.
authors.forename: O
authors.initials: O
authors.lastname: Sartor
authors.affiliation: Novartis, East Hanover, NJ, USA.
authors.forename: K
authors.initials: K
authors.lastname: Stein
authors.affiliation: Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: A V
authors.initials: AV
authors.lastname: D'Amico
authors.affiliation: Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: P L
authors.initials: PL
authors.lastname: Nguyen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D044383:Black People; D001918:Brachytherapy / Q000523:psychology; D004644:Emotions; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000473:pathology / Q000523:psychology*; D011446:Prospective Studies; D011468:Prostatectomy / Q000523:psychology; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000523:psychology*; D016896:Treatment Outcome